Two APOL1 risk variants—G1/G1, G1/G2 or G2/G2—indicate inherited kidney-disease susceptibility, not a diagnosis. Results can guide counseling, kidney monitoring and living-donor assessment without predicting an individual’s future with certainty.
- Two risk variants means G1/G1, G1/G2 or G2/G2; all three are classified as an APOL1 high-risk genotype.
- G1 is one risk allele even though the common G1 haplotype contains two linked sequence changes on the same chromosome.
- High risk is not a diagnosis: APOL1 results do not establish chronic kidney disease, focal segmental glomerulosclerosis or a need for dialysis.
- Kidney assessment needs two measurements: estimated glomerular filtration rate, or eGFR, and urine albumin-to-creatinine ratio, or ACR.
- Persistent kidney abnormalities include eGFR below 60 mL/min/1.73 m² or ACR of at least 30 mg/g for 3 months or longer.
- Normal baseline results often support an individualized annual monitoring plan, but no universal APOL1-specific screening interval is established.
- Genetic ancestry differs from race: ancestry can inform a testing discussion, but appearance and racial identity cannot determine an APOL1 genotype.
- Living donation requires separate counseling because two risk variants may affect eligibility even when current kidney measurements are normal.
- Family inheritance is predictable; disease is not: two parents with one risk allele each have a 25% chance of a child inheriting two risk alleles in each pregnancy.
What does an APOL1 high-risk genotype actually mean?
APOL1 유전자 검사 identifies inherited variants associated with kidney-disease susceptibility. Having two APOL1 risk variants—G1/G1, G1/G2 or G2/G2—raises risk but does not diagnose kidney disease or guarantee kidney failure; the next steps depend on kidney measurements, family history and whether donation is being considered.
A high-risk APOL1 result and chronic kidney disease are two different findings. A person can have G1/G2, an eGFR of 105 mL/min/1.73 m² and a urine ACR of 6 mg/g without evidence of current CKD; those measurements describe kidney health now, not a lifetime guarantee.
APOL1 testing is most useful when it changes a decision rather than simply adding a label. I’m Thomas Klein, Kantesti’s Chief Medical Officer, and I would separate three questions at the outset: what was inherited, whether kidney damage is present, and whether the result changes a donor or treatment discussion.
칸테스티는 AI 혈액검사 분석기 that can help explain kidney-related laboratory measurements, but a routine chemistry panel cannot reveal an APOL1 genotype. Our CKD 병기 설정 가이드 explains why eGFR and urine albumin must be considered together; neither measurement substitutes for a dedicated genetic assay.
How should G1/G1, G1/G2 and G2/G2 results be read?
G1/G1, G1/G2 and G2/G2 each mean that both inherited APOL1 gene copies carry a kidney-risk allele. G1/G1 contains two G1 alleles, G1/G2 contains one of each, and G2/G2 contains two G2 alleles; none is a kidney-function measurement.
G1 is usually a haplotype containing two linked coding changes, commonly described as S342G and I384M. Those changes generally travel together on one chromosome and count as one G1 risk allele, not two separate inherited risk alleles; G2 is a six-base-pair deletion that removes two amino acids from the APOL1 protein.
G0/G0, G0/G1 and G0/G2 are conventionally grouped as lower-risk APOL1 genotypes because they contain zero or one recognized risk allele. Lower APOL1 risk does not mean zero kidney-disease risk: diabetes, hypertension, other genetic conditions and medication-related injury remain possible, and limited assays do not examine every kidney-disease gene.
The three high-risk combinations are not reliable individual severity rankings. If a report lists sequence changes rather than an allele pair, ask the laboratory to translate them into an explicit genotype and state any limitations in determining which changes share a chromosome; our result-format explanation helps distinguish categorical genetic findings from numerical laboratory values.
Why don’t two APOL1 risk variants guarantee kidney disease?
APOL1-associated kidney susceptibility has incomplete penetrance: some people with two risk alleles develop kidney disease, while others do not. Age, additional genetic factors, immune signaling, environmental exposures and existing kidney conditions influence outcomes, so a genotype alone cannot provide a dependable personal lifetime percentage.
Parsa and colleagues reported that, among AASK participants who already had hypertension-associated CKD, the composite outcome of kidney failure or doubling serum creatinine occurred in 58.1% of the high-risk group versus 36.6% of the lower-risk group (Parsa et al., 2013). Those figures describe progression in an affected study population—not the chance that a healthy person with G1/G2 will develop CKD.
Relative risk and absolute risk answer different questions. Even a twofold association does not tell a person their probability without a relevant starting risk and a time horizon; a 30-year-old with normal ACR and a 65-year-old with substantial albuminuria should not receive the same prediction simply because their APOL1 results match.
The proposed “second-hit” model is useful but incomplete: certain immune or cellular stresses may increase APOL1-related injury, yet clinicians cannot identify a single required trigger for every patient. This resembles the distinction between susceptibility and diagnosis discussed in our ApoE4 risk explanation, although the genes, organs and predictive evidence are different.
How does genetic ancestry differ from race in APOL1 testing?
APOL1 G1 and G2 variants are associated particularly with genetic ancestry from parts of sub-Saharan Africa, not with a racial category itself. Race is a social classification, ancestry describes inherited population history, and neither a person’s appearance nor a single ancestry percentage establishes whether they carry zero, one or two risk alleles.
African ancestry is not one uniform genetic background. G1 and G2 frequencies differ substantially between populations, so a broad label such as “African,” “Black” or “mixed ancestry” is too coarse to establish an individual’s result; a family history extending across two or more regions can also be incomplete or unknown.
An ancestry-informed testing offer should be an invitation to discuss relevance, not a biological assumption about someone’s race. A person who does not identify as Black may carry two risk variants, while a person who does identify as Black may carry neither; asking about family origins is more respectful and clinically useful than inferring genetics from skin tone.
Race should not be used as a substitute for genotype or as an automatic adjustment to kidney-function interpretation. KDIGO 2024 supports avoiding race in eGFR computation; our Duffy-null neutrophil explanation illustrates another setting where a specific inherited finding is more informative than a racial label, although Duffy status does not predict APOL1 status.
Who may benefit from APOL1 genetic testing?
APOL1 testing may be useful for selected people with unexplained or familial kidney disease, some patients with focal segmental glomerulosclerosis, and potential living kidney donors with relevant ancestry. Testing everyone solely because of race is not an appropriate substitute for individualized consent, clinical assessment and a clear explanation of what the result could change.
An unexplained kidney problem before age 50, several relatives with kidney failure, or a tissue diagnosis showing FSGS can justify a genetics discussion. APOL1 may be only one part of that assessment: other inherited kidney disorders can produce similar findings, and a targeted APOL1 test will not identify all of them.
A positive APOL1 result does not prove that APOL1 caused every abnormality on a kidney panel. For example, G1/G1 in a patient with diabetes and an ACR of 450 mg/g may represent an additional susceptibility rather than a complete explanation; clinicians still assess diabetes duration, retinal findings, urine sediment, medication exposure and the pace of eGFR change.
Testing an unaffected relative should have an agreed purpose, such as counseling or donor evaluation, rather than a promise that it will prevent disease. Our inherited family-risk discussion shows why the question “What will we do differently after either result?” matters before ordering a genetic test; the appropriate answer can differ between two members of the same family.
How is the APOL1 test performed, and when is confirmation needed?
APOL1 genetic testing uses DNA, commonly obtained from a blood, saliva or cheek-swab specimen, to identify G1 and G2 alleles. The genotype normally remains unchanged throughout life, so one adequately performed clinical test is usually sufficient; repeat or confirmatory testing is reserved for uncertainty about specimen identity, assay coverage or the original result.
A clinical report should identify the tested variants, the genotype and the assay’s relevant limitations. Turnaround time varies between laboratories, and the genetic assay is separate from a same-day creatinine result; before paying, ask whether the fee includes counseling, whether both risk alleles are assessed, and whether an inconclusive result requires a second specimen.
An unexpected direct-to-consumer result may need confirmation in an accredited clinical laboratory before a transplant or other consequential decision. A screenshot showing two sequence changes is not necessarily proof of two risk alleles, particularly when the changes belong to the same G1 haplotype; the original report and its method matter more than an automated summary.
Kantesti’s laboratory explanations should preserve the distinction between genetic evidence and biochemical evidence rather than infer an APOL1 result from creatinine. Our 임상 검증 프레임워크 describes the standards behind laboratory interpretation, while our 의료 보고서 안전 가이드 explains why source verification is necessary before acting on a consequential result.
What should APOL1 genetic counseling cover for families?
APOL1 counseling should explain inheritance, uncertain disease prediction, family implications, privacy and the limits of testing. Each child inherits one APOL1 copy from each parent; predictable allele transmission does not translate into a predictable age of onset, disease severity or need for dialysis.
When both parents have one recognized APOL1 risk allele, each pregnancy has a 25% chance of two risk alleles, a 50% chance of one, and a 25% chance of none. These probabilities reset with every pregnancy; four children do not have to divide into those proportions, and a child inheriting two alleles is not thereby diagnosed with kidney disease.
A parent with G1/G2 passes a risk allele to every child: either G1 or G2, each with a 50% chance. If the other parent is G0/G0, none of their children will have two recognized risk alleles; a genetic counselor can explain when partner testing would meaningfully answer a family question rather than merely add anxiety.
Testing children requires a separate discussion about present medical benefit, consent and the child’s future autonomy—not simply applying an adult screening plan at age 8. Our carrier-screening counseling guide illustrates why inheritance terminology needs care, and our 연령별 가족 검사 가이드 helps distinguish targeted care from indiscriminate family screening.
Which kidney blood tests matter after a high-risk result?
Serum creatinine with eGFR is a standard blood-based assessment after an APOL1 high-risk result; cystatin C can improve assessment when creatinine is less reliable. Urine ACR must be added separately because an eGFR above 90 mL/min/1.73 m² does not rule out albumin leakage or early kidney damage.
Creatinine reflects both filtration and factors such as muscle mass, recent meat intake and some medications. A muscular adult with creatinine of 1.3 mg/dL may need a different interpretation from a frail adult with the same concentration; our muscular-adult creatinine guide explains why the laboratory flag alone is not a diagnosis.
A combined creatinine–cystatin C eGFR can be useful when a more accurate estimate could change a decision, including selected donor assessments. Cystatin C has its own influences, including glucocorticoid exposure and thyroid dysfunction, so it is not an infallible correction; our 시스타틴 C 해석 안내 discusses the two-marker approach.
칸테스티는 AI 혈액검사 결과 해석 플랫폼 that can help put serial creatinine and eGFR reports into context, but laboratory trends cannot prove APOL1-related disease. KDIGO 2024 states that an eGFR change greater than 20% on a subsequent test in someone with CKD exceeds expected variability and warrants evaluation; a smaller change can still matter when it persists or accompanies rising albuminuria.
How should urine ACR and follow-up timing be interpreted?
Urine ACR measures albumin leakage and is essential alongside eGFR when assessing APOL1 susceptibility. KDIGO albuminuria categories are A1 below 30 mg/g, A2 from 30–300 mg/g and A3 above 300 mg/g; persistent abnormalities require assessment even when filtration remains apparently normal.
One elevated ACR is not automatically persistent kidney damage. Strenuous exercise, fever, urinary infection and menstrual contamination can affect a result, so an ACR of 65 mg/g may need a properly timed repeat; our ACR 준비 가이드 explains practical collection steps without substituting a negative dipstick for a quantitative ratio.
An individualized annual review of blood pressure, eGFR and ACR is a reasonable discussion for an otherwise well adult with two risk alleles and normal baseline findings. That is a pragmatic monitoring plan, not a universal APOL1-specific guideline; established CKD, pregnancy, new hypertension or an abnormal trend may justify shorter intervals, such as 3–6 months, chosen by the treating clinician.
KDIGO 2024 considers a doubling of ACR on follow-up in someone with CKD a change that warrants evaluation. Urine microscopy adds a different kind of information: cellular casts or persistent red cells can point toward another process, as our 소변 침전물 가이드 explains; APOL1 testing should not make those findings disappear from the differential diagnosis.
When does an APOL1 result call for nephrology referral?
Nephrology referral is driven mainly by kidney abnormalities, progression, unexplained findings and donor questions—not by genotype alone. CKD requires evidence of abnormal kidney structure or function for at least 3 months; a rapidly changing creatinine result or concerning symptoms require prompt assessment without waiting for that chronicity threshold.
Persistent eGFR below 60 mL/min/1.73 m² or ACR at least 30 mg/g can satisfy CKD criteria when present for 3 months or longer. Referral urgency increases with advanced impairment, substantial albuminuria, a sustained downward trend or uncertainty about the cause; a normal eGFR does not make an ACR of 800 mg/g reassuring.
A hypothetical 36-year-old with G1/G2, eGFR 96 mL/min/1.73 m² and ACR 900 mg/g needs evaluation for significant albuminuria, not reassurance based on filtration alone. APOL1 susceptibility does not exclude membranous nephropathy or other glomerular disorders; our PLA2R antibody explanation describes one different diagnostic pathway that may become relevant when the clinical pattern fits.
Rapidly reduced urine output, breathlessness with swelling, or visible urine discoloration alongside worsening kidney measurements calls for urgent assessment. Some antibody-mediated conditions need especially rapid action, as discussed in our anti-GBM result guide; neither a known APOL1 result nor a 3-month CKD definition should delay an acute kidney evaluation.
Does a high-risk genotype change treatment or everyday habits?
An APOL1 high-risk genotype alone does not automatically justify kidney medication, a restrictive renal diet or supplements. Treatment depends on actual kidney disease, albuminuria, blood pressure and other conditions; proven CKD therapies should not be withheld merely because inherited susceptibility may contribute to the disease.
Blood-pressure control is a practical priority, but the measurement method changes how a target should be interpreted. KDIGO’s CKD guidance includes a standardized office systolic target below 120 mmHg when tolerated for appropriate adults; that is not an instruction to force every routine home reading below 120, especially with dizziness, frailty or other reasons to individualize treatment.
ACE inhibitors or ARBs and SGLT2 inhibitors may be indicated for particular CKD and albuminuria patterns, with monitoring of creatinine and potassium. Two risk alleles with normal eGFR and normal ACR do not automatically establish those indications; medication choices should follow the person’s documented condition and current local guidance rather than a genetic label.
No supplement, “kidney cleanse” or diet has been shown to erase G1 or G2 alleles. Avoid starting potassium restriction or a very-low-protein diet solely after a genetic result, and discuss frequent NSAID use with your clinician; our 신장 보충제 안전 가이드 explains why products marketed for kidney health can create problems rather than prevent them.
What do two APOL1 risk variants mean for living donation?
Two APOL1 risk variants may change living-kidney-donor eligibility even when current kidney function is normal. The concern is the donor’s future risk after losing kidney reserve, as well as possible implications for the donated kidney; transplant programs differ in how they incorporate the result into acceptance decisions.
The KDIGO living-donor guideline states that APOL1 genotyping may be offered to candidates with sub-Saharan African ancestry and that candidates should understand the uncertainty in predicting post-donation risk (Lentine et al., 2017). Many programs take a conservative approach to two risk alleles, particularly in younger candidates; there is no single internationally uniform APOL1 acceptance rule.
KDIGO 2017 considers donor GFR of at least 90 mL/min/1.73 m² generally acceptable, GFR from 60–89 individually assessable, and GFR below 60 unsuitable for donation. These filtration thresholds do not cancel APOL1 susceptibility; our BUN 및 크레아티닌 가이드를 참고하세요. explains why a reassuring chemistry result alone is not a complete donor assessment.
Age, albuminuria, blood pressure, family history and other health risks must be considered alongside the genotype. A young candidate has more remaining years in which disease could emerge, and related donors may share additional inherited risks; a transplant team should explain what a positive result means for eligibility before testing, not after a family has assumed donation will proceed.
How should APOL1 information be handled privately and safely?
APOL1 results are sensitive genetic information with implications for both the tested person and relatives. Before sharing a report with a clinical service or digital tool, check consent, access, retention and deletion options; protections against genetic discrimination differ between countries and between insurance products.
One person’s permission to share their result does not automatically authorize uploading a relative’s report. Remove unnecessary identifiers, consider who can access shared family accounts, and ask whether genetics information becomes part of a medical record; insurance and employment protections are jurisdiction-specific, so obtain local advice before assuming a general privacy statement covers every consequence.
칸테스티는 AI 바이오마커 해석 플랫폼 that can support understanding of kidney-related laboratory reports, but it does not replace APOL1 testing, genetic counseling or transplant eligibility review. Our 개인정보 및 데이터 관련 정보를 확인하고 explains data-handling considerations; an AI interpretation taking approximately 60 seconds is not the same service as completing a molecular genetic assay.
Kantesti LTD is a UK company, number 17090423, and our organization information provides context about who operates the service. Family Health Risk features should use consented information rather than infer a relative’s genotype from race, kidney chemistry or another person’s two-allele result; keep the original clinical laboratory report available for professional review.
What should you bring to your appointment, and which sources apply?
Bring the original APOL1 report, recent eGFR and urine ACR results, a medication list and a family kidney history to your appointment. As of October 19, 2026, this article distinguishes established guidance from uncertain individual prediction; its clinical references include the 2024 KDIGO CKD guideline and the 2017 KDIGO living-donor guideline.
A useful appointment can answer four concrete questions: Is kidney damage present, what is the monitoring interval, should relatives receive counseling, and does the result affect donation? My practical checklist as Thomas Klein, Chief Medical Officer at Kantesti, is to leave with a named clinician and a written next-test plan rather than an unsupported lifetime percentage; our 의료 자문 정보 describes the expertise behind our clinical standards.
Serum albumin and urine albumin answer different questions, and confusing the two can derail a kidney discussion. Our 혈청 단백질 가이드 provides supporting education on circulating proteins, but neither a normal serum albumin of 4.2 g/dL nor a normal albumin-to-globulin ratio excludes urinary albumin loss or determines an APOL1 genotype.
Complement tests are not routine APOL1 surveillance tests; C3 and C4 may become relevant when clinical findings suggest an immune-mediated kidney disorder. Our 보완 검사 가이드 is a supporting educational publication, not evidence for APOL1 penetrance; the two Zenodo resources listed below are separate from the directly relevant external medical references, and their ResearchGate and Academia.edu links are discovery searches rather than verified hosted copies.
자주 묻는 질문
APOL1 위험 변이가 두 개 있다고 해서 신장 질환에 걸리게 되나요?
APOL1 위험 변이 두 개를 보유하면 신장 질환에 걸릴 가능성이 높아지지만, 질환이나 신부전이 반드시 발생하는 것은 아닙니다. G1/G1, G1/G2, G2/G2는 모두 고위험 유전자형으로 분류되지만, 개인별 예후는 다릅니다. 현재의 신장 상태를 평가하려면 eGFR과 소변 ACR이 필요합니다. eGFR 100 mL/min/1.73 m²와 ACR 5 mg/g만으로는 CKD가 확진되지 않습니다. 이미 신장 질환이 있었던 사람들을 대상으로 한 연구의 백분율을 적용하기보다 개인별 모니터링 계획을 세우는 것이 더 유용합니다.
G1/G1, G1/G2, G2/G2는 심각도가 모두 같은가요?
G1/G1, G1/G2 및 G2/G2는 각각 인정된 APOL1 위험 대립유전자를 두 개씩 포함하며 고위험 유전자형으로 분류됩니다. 유전자형 조합만으로 개인의 향후 질병 중증도를 신뢰성 있게 순위화할 수는 없습니다. G1에는 흔히 하나의 염색체에 연결된 두 개의 서열 변화가 포함되지만, 이 변화들은 하나의 위험 대립유전자로 계산됩니다. 세 가지 조합 중 어느 것이든 해석하려면 신장 측정값, 연령 및 임상 병력이 여전히 필요합니다.
고위험 APOL1 결과가 나온 후 신장 검사는 얼마나 자주 받아야 하나요?
두 개의 위험 변이가 있는 모든 사람에게 일률적으로 적용되는 APOL1 특이적 모니터링 간격은 없습니다. 그 외에는 건강하고 기초 검사 결과가 정상인 성인의 경우, 연례 혈압, eGFR 및 소변 ACR 검사를 논의하는 것이 합리적인 출발점입니다. 기존 CKD, 알부민뇨 또는 변화하는 추세가 있는 경우 담당 임상의가 정하는 3~6개월과 같은 더 짧은 간격이 적절할 수 있습니다. 새로운 증상이나 신장 기능의 급격한 변화가 있으면 다음 예정 검사까지 기다리기보다 더 일찍 평가를 받아야 합니다.
APOL1 위험 변이가 두 개 있어도 신장을 기증할 수 있나요?
APOL1 위험 변이 두 개는 현재 신장 측정치가 정상인 경우에도 생체 신장 기증자 자격에 영향을 줄 수 있습니다. 이식 프로그램마다 수용 정책이 다르며, 개인별 기증 후 위험을 정확히 예측할 수 없으므로 보수적인 접근법을 사용하는 곳이 많습니다. KDIGO 생체 기증자 지침에서는 일반적으로 GFR 90 mL/min/1.73 m² 이상을 허용 가능한 것으로 보지만, 이 기준이 유전적 위험이나 기타 건강 위험보다 우선하는 것은 아닙니다. 정상 크레아티닌 수치만으로 기증자의 안전성이 입증된다고 여기기 전에 해당 프로그램의 APOL1 정책에 관해 상담을 받으십시오.
APOL1 검사는 흑인이라고 정체성을 밝히는 사람에게만 해당되나요?
APOL1 검사는 인종 정체성에 국한되지 않습니다. 유전적 조상과 인종은 서로 다른 개념이기 때문입니다. G1과 G2는 특히 사하라 이남 아프리카 일부 지역의 조상과 관련이 있지만, 외모만으로는 위험 대립유전자가 0개, 1개 또는 2개인지 확인할 수 없습니다. 자신을 흑인이라고 여기지 않는 사람도 이러한 변이를 보유할 수 있고, 자신을 흑인이라고 여기는 사람도 둘 다 보유하지 않을 수 있습니다. 검사에 관한 논의에서는 조상, 신장 소견, 가족력, 그리고 검사 결과가 바꿀 수 있는 결정 사항을 고려해야 합니다.
내 자녀들이 APOL1 위험 변이 두 개를 물려받을까요?
자녀의 APOL1 유전자형은 부모 각각에게서 물려받은 대립유전자에 따라 달라집니다. 부모 모두 위험 대립유전자를 하나씩 가지고 있다면, 임신마다 자녀가 위험 대립유전자 두 개를 물려받을 확률은 25%입니다. 한쪽 부모가 G1/G2이고 다른 쪽 부모가 G0/G0이면, 모든 자녀가 위험 대립유전자 하나를 물려받고, 두 개의 알려진 위험 대립유전자를 물려받는 자녀는 없습니다. 이러한 유전 확률로는 신장 질환의 발병 여부나 시기를 예측할 수 없습니다.
오늘 AI 기반 혈액검사 분석 받기
즉시 정확한 검사 분석을 위해 Kantesti를 신뢰하는 전 세계 200만 명 이상의 사용자와 함께하세요. 혈액검사 결과를 업로드하고 몇 초 만에 15,000+ 바이오마커에 대한 포괄적인 해석을 받아보세요.
📚 참고된 연구 출판물
📖 외부 의학 참고문헌
Parsa A et al. (2013). APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease. 뉴잉글랜드 의학저널(NEJM).
Lentine KL et al. (2017). KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. 이식.
신장질환: 글로벌 결과 개선(KDIGO) CKD 작업반 (2024). KDIGO 2024 만성 신장질환 평가 및 관리를 위한 임상진료지침. Kidney International.
⚕️ 의료 면책 조항
이 글은 교육 목적만을 위한 것이며 의학적 조언을 구성하지 않습니다. 진단 및 치료 결정에는 항상 자격을 갖춘 의료 전문가와 상담하세요.
E-E-A-T 신뢰 신호
경험
의사가 주도하는 검사 해석 워크플로 임상 검토.
전문적 지식
임상 맥락에서 바이오마커가 어떻게 거동하는지에 대한 검사실 의학 중심.
권위
Dr. Thomas Klein이 작성했으며 Dr. Sarah Mitchell과 Prof. Dr. Hans Weber가 검토했습니다.
신뢰성
경고를 줄이기 위한 명확한 후속 경로가 포함된 근거 기반 해석.